3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
37
Carcinoma, Non-Small-Cell Lung
28
Glioblastoma
24
Brain Neoplasms
23
Esophageal Neoplasms
20
Rectal Neoplasms
19
Stomach Neoplasms
17
Glioma
17
Lung Neoplasms
16
Colorectal Neoplasms
16
Astrocytoma
14
Pancreatic Neoplasms
12
Central Nervous System Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Neoplasm Metastasis
10
Head and Neck Neoplasms
10
Gliosarcoma
10
Sarcoma
9
Oligodendroglioma
9
Recurrence
8
Neoplasms
8
Adenocarcinoma Of Esophagus
8
Esophageal Squamous Cell Carcinoma
7
Uterine Cervical Neoplasms
6
Ovarian Neoplasms
6
Colonic Neoplasms
6
Pilonidal Sinus
5
Melanoma
5
Carcinoma, Ovarian Epithelial
5
Adenocarcinoma of Lung
5
Interventions
pembrolizumab
124
Cisplatin
27
lenvatinib
24
Carboplatin
24
Paclitaxel
19
Docetaxel
16
Fluorouracil
13
Capecitabine
11
Pemetrexed
10
Gemcitabine
10
Saline Solution
8
Oxaliplatin
8
epacadostat
6
Leucovorin
5
Irinotecan
5
Cetuximab
5
olaparib
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
trifluridine tipiracil drug combination
3
regorafenib
3
enzalutamide
3
durvalumab
3
Nivolumab
3
Etoposide
3
trametinib
2
etoposide phosphate
2
dabrafenib
2
Tretinoin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Surgical Procedures, Operative
×
Clear all
NCT03924856
2026-05-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3
Completed
907 enrolled
NCT04700124
2026-02-05
KEYNOTE-B15
Merck Sharp & Dohme LLC
Phase 3
Completed
808 enrolled